Global private funding for HIV amounted to $618 million in 2014, a growth of 8 percent from the previous year, according to the latest annual report from Funders Concerned About AIDS (FCAA).

The increase resulted from boosted monies from two main groups: the Bill & Melinda Gates Foundation and Gilead Sciences, according to an FCAA press release on the report. Global funding has remained between $600 million and $650 million for the past eight years.

“While we celebrate this encouraging headline, the full story is more complex,” John L. Barnes, FCAA executive director, said in the press release. “Despite the overall increase, private philanthropic funding for HIV/AIDS is still down 8 percent from the high water mark set in 2008 ($674 million), even at the height of the global economic crisis.”

MAC AIDS Fund, Wellcome Trust and the Ford Foundation rounded out the top five philanthropic HIV funders of 2014.

Private funding directed toward the U.S. epidemic totaled  $139 million, which marks a record high and makes the United States the top recipient of HIV funds for 2014. Most of that money came from Gilead, which manufactures several HIV medicines.

The report was released during the FCAA 2015 AIDS Philanthropy Summit.